$XBIT
XBiotech Inc

2017 Q2 Form 10-Q Financial Statement

#000117184317004856 Filed on August 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.290M $2.400M
YoY Change -4.58% 17.65%
% of Gross Profit
Research & Development $7.399M $11.22M
YoY Change -34.03% 155.96%
% of Gross Profit
Depreciation & Amortization $290.0K $170.0K
YoY Change 70.59% 0.0%
% of Gross Profit
Operating Expenses $9.688M $13.62M
YoY Change -28.84% 112.04%
Operating Profit -$9.688M -$13.62M
YoY Change -28.84% -312.04%
Interest Expense $560.0K -$10.00K
YoY Change -5700.0% -96.88%
% of Operating Profit
Other Income/Expense, Net $555.0K -$7.000K
YoY Change -8028.57% -97.83%
Pretax Income -$9.130M -$13.62M
YoY Change -32.97% 102.08%
Income Tax
% Of Pretax Income
Net Earnings -$9.133M -$13.62M
YoY Change -32.95% 101.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$258.5K -$420.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $45.90M $64.80M
YoY Change -29.17% -44.8%
Cash & Equivalents $45.95M $64.80M
Short-Term Investments
Other Short-Term Assets $1.400M $1.500M
YoY Change -6.67% -50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $47.30M $66.33M
YoY Change -28.69% -44.91%
LONG-TERM ASSETS
Property, Plant & Equipment $30.54M $9.779M
YoY Change 212.3% 50.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $30.54M $26.87M
YoY Change 13.65% 319.89%
TOTAL ASSETS
Total Short-Term Assets $47.30M $66.33M
Total Long-Term Assets $30.54M $26.87M
Total Assets $77.84M $93.20M
YoY Change -16.48% -26.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.385M $8.494M
YoY Change -60.15% 269.3%
Accrued Expenses $1.278M $1.882M
YoY Change -32.09% 213.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.663M $10.38M
YoY Change -55.06% 257.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.663M $10.38M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.685M $10.40M
YoY Change -54.94% 258.52%
SHAREHOLDERS EQUITY
Retained Earnings -$203.1M -$154.5M
YoY Change 31.44%
Common Stock $276.6M $237.5M
YoY Change 16.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.16M $82.80M
YoY Change
Total Liabilities & Shareholders Equity $77.84M $93.20M
YoY Change -16.48% -26.5%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income -$9.133M -$13.62M
YoY Change -32.95% 101.99%
Depreciation, Depletion And Amortization $290.0K $170.0K
YoY Change 70.59% 0.0%
Cash From Operating Activities -$8.470M -$8.250M
YoY Change 2.67% -6.88%
INVESTING ACTIVITIES
Capital Expenditures -$280.0K -$5.850M
YoY Change -95.21% 256.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$280.0K -$5.850M
YoY Change -95.21% 256.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 560.0K 710.0K
YoY Change -21.13% -99.06%
NET CHANGE
Cash From Operating Activities -8.470M -8.250M
Cash From Investing Activities -280.0K -5.850M
Cash From Financing Activities 560.0K 710.0K
Net Change In Cash -8.190M -13.39M
YoY Change -38.83% -120.65%
FREE CASH FLOW
Cash From Operating Activities -$8.470M -$8.250M
Capital Expenditures -$280.0K -$5.850M
Free Cash Flow -$8.190M -$2.400M
YoY Change 241.25% -66.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3385000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4431000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1278000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3532000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-326000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
898000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1098000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1622000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2914000
CY2017Q2 us-gaap Assets
Assets
77841000
CY2016Q4 us-gaap Assets
Assets
67050000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
47301000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
36930000
CY2017Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
122000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
581000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45949000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34324000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91051000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
99000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64798000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11625000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-26253000
CY2017Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35419772
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32627691
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
276589000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
242419000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9626000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13648000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20079000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23867000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><!-- Field: /Page --> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution. These amounts at times <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any credit losses in such accounts and does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to any significant credit risk on these funds. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div></div></div>
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
1550000
CY2017Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
19978000
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
23000
us-gaap Depreciation
Depreciation
592000
us-gaap Depreciation
Depreciation
350000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-383000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
12000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y193D
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3500000
CY2017Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
441000
CY2016Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2289000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2399000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4372000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4835000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1167000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1536000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2254000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
416000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1255000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-460000
CY2017Q2 us-gaap Investment Income Net
InvestmentIncomeNet
114000
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
us-gaap Investment Income Net
InvestmentIncomeNet
164000
us-gaap Investment Income Net
InvestmentIncomeNet
CY2017Q2 us-gaap Liabilities
Liabilities
4685000
CY2016Q4 us-gaap Liabilities
Liabilities
7986000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77841000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67050000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4663000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7963000
CY2017Q2 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
CY2016Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
0
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
33274000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
707000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-890000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8774000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20376000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18198000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-9133000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-13622000
us-gaap Net Income Loss
NetIncomeLoss
-19696000
us-gaap Net Income Loss
NetIncomeLoss
-23879000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
555000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
263000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
9688000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
13615000
us-gaap Operating Expenses
OperatingExpenses
19959000
us-gaap Operating Expenses
OperatingExpenses
23863000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9688000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13615000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19959000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23863000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-493000
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-26000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-383000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3602000
CY2017Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2016Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1352000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2606000
CY2016Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31600000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
654000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
707000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
32620000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1100000
CY2017Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
454000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30540000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10142000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7399000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11216000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15587000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19028000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-203107000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183412000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
87000
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2400000
us-gaap Share Based Compensation
ShareBasedCompensation
896000
us-gaap Share Based Compensation
ShareBasedCompensation
2914000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
235370
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
880000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.66
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.64
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5188658
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5446121
CY2016Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
145000
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
204000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
66000
CY2017Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
204000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
387167
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
315000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
73156000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
59064000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Prior to its initial public offering on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 15, 2015, </div>the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company&#x2019;s common stock based on a number of objective and subjective factors, including the prices at which the Company sold shares of its common stock to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and external market conditions affecting the biotechnology industry sector. After the initial public offering, the fair market value is calculated by using the closing price of the Company&#x2019;s common stock as reported by NASDAQ.</div></div></div></div>
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35320499
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32378412
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34311690
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32333199
xbit Payments For Proceeds From Construction In Process
PaymentsForProceedsFromConstructionInProcess
xbit Payments For Proceeds From Construction In Process
PaymentsForProceedsFromConstructionInProcess
5172000

Files In Submission

Name View Source Status
0001171843-17-004856-index-headers.html Edgar Link pending
0001171843-17-004856-index.html Edgar Link pending
0001171843-17-004856.txt Edgar Link pending
0001171843-17-004856-xbrl.zip Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10q_080817p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbit-20170630.xml Edgar Link completed
xbit-20170630.xsd Edgar Link pending
xbit-20170630_cal.xml Edgar Link unprocessable
xbit-20170630_def.xml Edgar Link unprocessable
xbit-20170630_lab.xml Edgar Link unprocessable
xbit-20170630_pre.xml Edgar Link unprocessable